GLP-1 & MetabolicResearch OnlyS

AOD-9604

HGH Fragment 176-191

AOD-9604 is a modified C-terminal fragment (residues 176–191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties. Unlike full HGH, AOD-9604 lacks growth-promoting or diabetogenic effects but retains the fat-burning activity attributed to HGH's C-terminus. Phase IIb/III trials were conducted for obesity but fell short of the primary endpoint. Research only in the US.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
3
Research grade
S
Community score
130

Trend index

Trackers
2,320

Overview

About AOD-9604

AOD-9604 is a modified C-terminal fragment (residues 176–191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties. Unlike full HGH, AOD-9604 lacks growth-promoting or diabetogenic effects but retains the fat-burning activity attributed to HGH's C-terminus. Phase IIb/III trials were conducted for obesity but fell short of the primary endpoint. Research only in the US.

Category
GLP-1 & Metabolic
Regulatory status
Research Only
Also known as
HGH Fragment 176-191
Self-reports
44

Community

What 44 users report

44 community reports

Positive 98% · Neutral 2% · Negative 0%

Most reported benefits

Appetite
155
Recovery
155

Most reported side effects

Headache
2
Injection site irritation
1

Dose distribution

Median: 200–400 mcg · Most common: 200–400 mcg

0–25
0
25–50
0
50–100
0
100–200
4
200–400
113
400–600
37
600–1000
0
1000–2000
0
2000+
1

How repeat users are trending

Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.

Overall, repeat reporters leaned similar or mixed compared to their previous entry.

Median gap between entries: 54 days · Based on 30 repeat reporters

Research

Cited research (2)

Help

Frequently asked

What do PeptIQ users report about AOD-9604?

This page summarizes 44 anonymized self-reports from PeptIQ users who track AOD-9604, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for AOD-9604?

2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is AOD-9604 safe to use?

This wiki does not assess safety or recommend use. AOD-9604 is listed as Research Only. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of AOD-9604?

Research, primarily in animal models, suggests AOD-9604 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of AOD-9604?

AOD-9604 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified AOD-9604 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of AOD-9604?

The safety and effectiveness of AOD-9604 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on AOD-9604?

While there are over 200 published studies on AOD-9604, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source